Mario A. Eisenberger - Researcher Profile

Publications

3 shown

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Christos E. Kyriakopoulos , Yu‐Hui Chen , Michael A. Carducci +15 more

Purpose Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, w...

2018 Journal of Clinical Oncology 1049 citations

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer

Ryan Phillips , William Y. Shi , Matthew P. Deek +23 more

ClinicalTrials.gov Identifier: NCT02680587.

2020 JAMA Oncology 1037 citations

Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone

Eric J. Small , Mark Meyer , M. Ernest Marshall +7 more

PURPOSE: Suramin is a novel agent that has demonstrated preliminary evidence of antitumor activity in hormone-refractory prostate cancer (HRPC). A prospective randomized clinica...

2000 Journal of Clinical Oncology 188 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 2,274
Institution: Dana-Farber Cancer Institute

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-8787-3271

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.